

# Robin J Prescott

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3959451/robin-j-prescott-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10  
papers

1,025  
citations

7  
h-index

13  
g-index

13  
ext. papers

1,115  
ext. citations

3.7  
avg, IF

3.67  
L-index

#	Paper	IF	Citations
10	Reliability testing of the heel marker in three-dimensional gait analysis. <i>Gait and Posture</i> , <b>2021</b> , 85, 84-87	2.6	1
9	Response to comments on "Two-tailed significance tests for 2x2 contingency tables: What is the alternative?". <i>Statistics in Medicine</i> , <b>2020</b> , 39, 99-101	2.3	
8	Validation of the foot profile score. <i>Gait and Posture</i> , <b>2019</b> , 71, 120-125	2.6	6
7	Two-tailed significance tests for 2x2 contingency tables: What is the alternative?. <i>Statistics in Medicine</i> , <b>2019</b> , 38, 4264-4269	2.3	9
6	Lies, damn lies and statistics: errors and omission in papers submitted to INJURY 2010-2012. <i>Injury</i> , <b>2013</b> , 44, 6-11	2.5	8
5	A step in the right direction. <i>Gait and Posture</i> , <b>2006</b> , 23, 131-2	2.6	1
4	Reply to Labrie et al. Results of the mortality analysis of the Quebec Randomized/controlled trial (RCT). <i>Prostate</i> , <b>1999</b> , 40, 135-7	4.2	14
3	Reply to Labrie et al. <b>1999</b> , 40, 135		8
2	Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). <i>Circulation</i> , <b>1998</b> , 98, 1510-6	16.7	919
1	A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. <i>Leukemia and Lymphoma</i> , <b>1992</b> , 7 Suppl, 17-20	1.9	38